Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report)'s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $14.85. Crescent Biopharma shares last traded at $13.50, with a volume of 321,487 shares changing hands.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the company. Lifesci Capital raised Crescent Biopharma to a "strong-buy" rating and set a $22.00 price target for the company in a report on Wednesday, June 18th. TD Cowen raised Crescent Biopharma to a "strong-buy" rating in a report on Friday, June 20th. Finally, Stifel Nicolaus assumed coverage on Crescent Biopharma in a report on Wednesday, June 25th. They issued a "buy" rating and a $28.00 price target for the company.
Get Our Latest Stock Report on CBIO
Crescent Biopharma Stock Down 8.7%
The firm has a market cap of $263.93 million, a PE ratio of -0.29 and a beta of 1.52.
Crescent Biopharma Company Profile
(
Get Free Report)
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Crescent Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.
While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
